Rigel Pharmaceuticals, Inc. (RIGL) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong financial performance with significant year-over-year sales growth across key products, despite a slight net income decline due to higher R&D and operational expenses. The Q&A section reveals management's strategic focus on hematology/oncology, with promising developments for R289. Although some details were unclear, the overall sentiment is positive, supported by a robust revenue increase and strategic product focus. Given the company's small-cap status, the stock is likely to react positively, falling into the 2% to 8% range over the next two weeks.
Key Financial Performance
Net Product Sales $54.9 million in Q1 2026, a 26% increase year-over-year. Growth attributed to stronger demand and favorable gross-to-net adjustments.
TAVALISSE Net Product Sales $37.3 million in Q1 2026, a 31% increase year-over-year. Growth driven by stronger demand and favorable gross-to-net adjustments.
GAVRETO Net Product Sales $9.6 million in Q1 2026, a 7% increase year-over-year. Growth attributed to stable contribution to the portfolio.
REZLIDHIA Net Product Sales $8 million in Q1 2026, a 31% increase year-over-year. Growth driven by increased adoption in academic accounts and community settings.
Contract Revenues $3.9 million in Q1 2026. Includes $1.8 million from Grifols (earned royalties), $1.8 million from Kissei (drug supplies), and $300,000 from Medison (drug supply and royalties).
Total Revenue $58.8 million in Q1 2026, combining net product sales and contract revenues.
Cost of Product Sales $4.6 million in Q1 2026.
Total Costs and Expenses $46.9 million in Q1 2026, up from $40.6 million in Q1 2025. Increase due to higher R&D costs, commercial-related expenses, and personnel-related costs.
Net Income $8.7 million in Q1 2026, down from $11.4 million in Q1 2025. Decrease attributed to increased costs and expenses.
Cash, Cash Equivalents, and Short-term Investments $146.7 million as of Q1 2026, down from $155 million at the end of 2025. Decrease due to operational funding.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Net Product Sales: Generated $54.9 million in Q1 2026, a 26% increase year-over-year. TAVALISSE sales grew 31% to $37.3 million, GAVRETO sales grew 7% to $9.6 million, and REZLIDHIA sales grew 31% to $8 million.
R289 Program: Progressing in lower-risk MDS with data expected by year-end. Phase Ib study shows promising safety and efficacy, with 33% of patients achieving transfusion independence.
Product Portfolio: Expanded to three commercial products (TAVALISSE, REZLIDHIA, GAVRETO) approved across four indications.
Global Expansion: TAVALISSE is available in Europe, Japan, South Korea, Canada, and Israel. Partners are pursuing regulatory approvals in new markets. REZLIDHIA expanded to several Asian countries and territories through partnerships with Kissei and Dr. Reddy's.
Revenue Guidance: Maintained 2026 revenue guidance of $275-$290 million, including $255-$265 million in net product sales.
Profitability: Achieved net income profitability in Q3 2024 and maintained profitability through Q1 2026.
Debt Restructuring: Replaced term loan credit facility with a $40 million revolving credit facility, providing cost-efficient financing.
Growth Strategy: Focused on commercial execution, pipeline expansion through in-licensing or acquisitions, advancing clinical development, and maintaining financial discipline.
In-Licensing and Acquisitions: Targeting late-stage assets in hematology and oncology for potential launches between 2026 and 2028.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory and Product Development Risks: The company acknowledges risks and uncertainties related to regulatory and product development, which may cause actual results to differ from forecasts. These risks are tied to the timing and success of regulatory approvals and product development.
Seasonal Reimbursement Dynamics: First-quarter net sales were impacted by seasonal reimbursement dynamics, including resetting of deductibles, co-pays, and access delays for Medicare patients. These factors could affect revenue consistency.
Dependence on In-Licensing and Acquisitions: The company’s growth strategy heavily relies on in-licensing or acquiring late-stage assets. Failure to secure such assets could hinder future growth and revenue expansion.
Pipeline Development Challenges: The development of R289 and other pipeline products involves clinical and regulatory risks. Delays or failures in clinical trials or regulatory approvals could impact the company’s ability to expand its portfolio.
Collaboration Termination: Lilly’s termination of the collaboration on the RIPK1 asset (ocusertib) could impact the company’s development pipeline and future revenue opportunities.
Financial Risks: The company restructured its debt agreement, which introduces financial risks related to the repayment and utilization of the revolving credit facility. Additionally, maintaining positive net income while funding clinical developments poses a financial challenge.
Market Access and Adoption Risks: The adoption of products like REZLIDHIA in the community and the expansion of TAVALISSE in global markets depend on regulatory approvals and market acceptance, which are not guaranteed.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for 2026: The company expects total revenue in the range of $275 million to $290 million, including net product sales of $255 million to $265 million and $20 million to $25 million of contract revenues.
Profitability Outlook: Rigel anticipates achieving net income profitability for the full year 2026.
R289 Program in Lower-Risk MDS: The company plans to complete enrollment of the dose expansion phase of the R289 study and select the recommended Phase II dose in the second half of 2026. Top-line data from the dose expansion phase is expected by the end of 2026. A potential registration study for R289 may initiate in 2027.
In-Licensing and Acquisition Strategy: Rigel is actively evaluating late-stage in-license or acquisition opportunities with potential commercial launches between 2026 and 2028. The focus is on differentiated assets in hematology, oncology, and related areas.
Commercial Product Growth: The company expects continued growth in its commercial products, including TAVALISSE, GAVRETO, and REZLIDHIA, driven by new patient starts and improved adoption, particularly in the community setting.
Global Expansion: Rigel's partners are pursuing regulatory approvals for TAVALISSE and REZLIDHIA in new markets, with ongoing efforts to expand access outside the U.S.
Debt Restructuring: The company replaced its term loan credit facility with a revolving credit facility, providing cost-efficient and flexible financing for future operations.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you please talk about your plans for the RIPK1 inhibitor now and maybe comment on Lilly's rationale for terminating the agreement?
A:Rigel's CEO, Raul Rodriguez, explained that the RIPK1 inhibitor was not a strategic focus for Rigel, as the company is primarily focused on hematology/oncology. The partnership with Lilly was financially beneficial, as RIPK1's primary focus is in immunology and CNS diseases, which are better suited for a larger pharma company like Lilly. Rigel will assess the next steps for RIPK1, but it remains a non-core focus for the company.
Q:Are there any other drivers or key factors that are rate-limiting steps for growing the community centers for REZLIDHIA?
A:David Santos, EVP & Chief Commercial Officer, highlighted that community physicians do not frequently treat AML or IDH1 mutated AML, leading to a reliance on familiar treatments. Rigel is working to overcome this by providing targeted messaging and data to community clinicians at the right time, particularly when they have an IDH1 patient. The goal is to educate them on the compelling data for REZLIDHIA.
Q:What would be the important benchmarks or signals for R289 to proceed to a potential registrational study design?
A:Lisa Rojkjaer, EVP & Chief Medical Officer, stated that benchmarks include consistent safety, evidence of activity, and improvement in anemia in heavily pretreated patients. Raul Rodriguez added that R289's novel, oral, and chronic-use profile is promising, and the company is awaiting larger data sets by the end of the year to make further decisions.
Q:What do you see as an acceptable safety profile for R289, and how will that play into the dose selection for Phase II?
A:Lisa Rojkjaer noted that the safety profile so far is encouraging, with a low incidence of cytopenias and infections in elderly, heavily pretreated patients. The oral administration of R289 is also a positive factor. The company hopes to maintain this safety profile as more patients are enrolled.
Q:What has been the feedback on GAVRETO revenue, and can you provide details on new patient starts, switches, and persistence rates?
A:David Santos explained that Rigel does not provide specific details on new patient starts or persistence rates. GAVRETO has a targeted market with high awareness among clinicians, particularly in lung cancer. The product generates around $10 million per quarter, and Rigel is focusing its efforts on growing revenues for REZLIDHIA and TAVALISSE instead of incremental growth for GAVRETO.
Q:Are there specific patient baseline profiles being enrolled in the R289 dose expansion study relative to dose escalation cohorts?
A:Lisa Rojkjaer mentioned that the company anticipates providing an update on the study at the end of the year. Raul Rodriguez added that the earlier dose escalation phase included elderly, heavily pretreated, and highly refractory patients, but further details on the current expansion phase are not yet available.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on GAVRETO's new patient starts, switches, and persistence rates, as well as on the patient baseline profiles for the R289 dose expansion study. Their responses lacked clarity and detail in these areas.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Asia
Executive VP
II study
Ib study
Lilly collaboration
Medicare patient
National
Phase Ib
RBCTI week
REZLIDHIA GAVRETO
Slide revenue
Today
VP Chief
adoption
adult patient
community
credit facility
dose study
escalation phase
foundation
launch
milligram
patient dos
patient population
pattern
product portfolio
profitability
reimbursement dynamic
sale factor
stage asset
step development
study Phase
term loan
termination
trend
update study
volume
week patient
RIGL Transcript
Rigel Pharmaceuticals, Inc. (RIGL) Q1 2026 Earnings Call Transcript
Positive5-6
The earnings call highlights strong financial performance with significant year-over-year sales growth across key products, despite a slight net income decline due to higher R&D and operational expenses. The Q&A section reveals management's strategic focus on hematology/oncology, with promising developments for R289. Although some details were unclear, the overall sentiment is positive, supported by a robust revenue increase and strategic product focus. Given the company's small-cap status, the stock is likely to react positively, falling into the 2% to 8% range over the next two weeks.
Rigel Pharmaceuticals, Inc. (RIGL) Q4 2025 Earnings Call Transcript
Positive3-3
The earnings call indicates strong financial performance with significant revenue and net income growth, a raised revenue guidance for 2025, and strategic product development plans. Despite some uncertainties in global market access and management's vague responses in the Q&A, the overall sentiment is positive due to the raised guidance and strong financial metrics. The market cap suggests a moderate reaction, leading to a predicted stock price movement of 2% to 8%.
Rigel Pharmaceuticals, Inc. (RIGL) Q3 2025 Earnings Call Transcript
Positive11-4
The earnings call highlighted strong financial performance with record revenue and net income, a raised revenue guidance for 2025, and significant product sales growth. Despite some uncertainties in product development and strategic collaborations, the market reacted positively to the optimistic guidance and financial discipline. The Q&A revealed management's cautious optimism and focus on strategic growth, without major negative surprises. Given the company's small-cap status, the positive financial results and guidance are likely to drive a stock price increase in the short term.
Rigel Pharmaceuticals, Inc. (RIGL) Q2 2025 Earnings Call Transcript
Positive8-5
The earnings call reveals strong financial performance with a 76% increase in net product sales and a significant net income turnaround. The company's strategic partnerships and product demand growth, particularly for GAVRETO, are positive indicators. Despite some risks in strategic execution and global expansion, the optimistic guidance and financial discipline suggest a positive stock price movement. The market cap indicates a potential for notable reaction, but not extreme, leading to a 'Positive' sentiment.
RIGL Slides
RIGL Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
